Diligence memo · auto-generated · as of July 2, 2026
Evolus, Inc.
Evolus, Inc. looks over-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Evolus, Inc. operates in Pharmaceuticals, based in Newport Beach.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Evolus, Inc. has raised $41M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $40M on 2020-07-06.
Most recent recorded round closed around 2020-07-06.
Valuation (modeled)modeled
Provath models Evolus, Inc. at approximately $1.4B (range $84M–$5.2B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 2.74× the median modeled value of Series B Pharmaceuticals companies in 2019–2021 (61 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 88 months.
Last raise 6.0 yr ago; this sector typically re-raises about every 13 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 80.0× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 78% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 92% of those peers.
Closest niche peers: HOOKIPA Pharma Inc., ESSA Pharma Inc., Pieris Pharmaceuticals, Inc., Amylyx Pharmaceuticals, Inc., PassPort Technologies, Inc..
Peoplefiled
13 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.